FDA Approved: INSULIN GLARGINE — Supplemental Application (Biocon Biologics Inc.)

View source ↗

Summary

FDA approved a supplemental application for INSULIN GLARGINE-YFGN from Biocon Biologics Inc., authorizing its biosimilar insulin glargine product.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 1 Diabetes Mellitus
• Type 2 Diabetes Mellitus

Drugs mentioned

• Insulin Glargine (insulin glargine)

Snippet

SUPPL AP for INSULIN GLARGINE (INSULIN GLARGINE-YFGN)